Hyderabad-based Bharat Biotech has completed the Phase second and third clinical trials of coronavirus vaccine, Covaxin for use in the age group of 2 to 18 years. Bharat Biotech is expected to submit the data by next week to the DCGI.
Sharing details before media, Chairman and Managing Director of Bharat Biotech International Ltd, Krishna Ella said Covaxin production would touch 55 million doses in October as against 35 million in September. He also said the Phase 2 trials of the firm's intranasal vaccine against COVID-19 are expected to be over by next month. The number of volunteers is touching 1000," Ella said.
Intranasal immunization can create an immune response in the nose, which is the point of entry for the virus-thereby protecting against the disease, infection, and transmission also, he noted. He said, the intranasal vaccine trials are conducted on three cohorts in which one group is administered Covaxin as the first dose and intranasal as the second. Similarly intranasal-intranasal for the second group and Intranasal- Covaxin for the third cohort, 28 days apart. He added the trials will be conducted on about 650 volunteers. On the production levels of Covaxin, Ella said 100 million doses per month can be possible if the other manufacturing partners are fully geared up with safety and other parameters are in place.